Breaking News Instant updates and real-time market news.

FORR

Forrester

$43.85

0.05 (0.11%)

, RST

Rosetta Stone

$17.01

0.69 (4.23%)

07:18
07/10/18
07/10
07:18
07/10/18
07:18

OpenText to hold a conference

OpenText Enterprise World 2018 will be held in Toronto, Canada on July 10-12.

FORR

Forrester

$43.85

0.05 (0.11%)

RST

Rosetta Stone

$17.01

0.69 (4.23%)

F

Ford

$11.20

0.14 (1.27%)

DPS

Ticker changed to KDP

$0.00

(0.00%)

SIEGY

Siemens

$0.00

(0.00%)

GSK

GlaxoSmithKline

$41.01

-0.01 (-0.02%)

ALL

Allstate

$93.62

1.46 (1.58%)

VZ

Verizon

$50.75

-0.13 (-0.26%)

SAP

SAP

$119.25

2.26 (1.93%)

OTEX

OpenText

$36.94

0.51 (1.40%)

  • 10

    Jul

  • 10

    Jul

  • 10

    Jul

  • 10

    Jul

  • 11

    Jul

  • 12

    Jul

  • 19

    Jul

  • 25

    Jul

  • 25

    Jul

  • 02

    Aug

  • 02

    Aug

  • 06

    Aug

  • 15

    Aug

  • 28

    Oct

FORR Forrester
$43.85

0.05 (0.11%)

RST Rosetta Stone
$17.01

0.69 (4.23%)

03/19/18
LSCM
03/19/18
NO CHANGE
Target $16
LSCM
Buy
Rosetta Stone price target raised to $16 from $14 at Lake Street
Lake Street analyst Eric Martinuzzi raised his price target for Rosetta Stone to $16 from $14 following the company's Q4 results. The analyst expects 2018 to be Rosetta's first full year of positive sales comp in over five years. He keeps a Buy rating on the shares.
03/08/18
BRRR
03/08/18
NO CHANGE
BRRR
Rosetta Stone price target raised to $17 from $15 at Barrington
Barrington analyst Alexander Paris, Jr. reiterated an Outperform rating on Rosetta Stone and raised his price target to $17 from $15 on the shares, after the company reported Q4 earnings results, with EPS coming in better than both the firm's and the consensus expectations. However, the analyst noted that Q4 revenue and FY18 guidance came in below expectations. Paris concluded that he would be a buyer of Rosetta Stone, especially into weakness, given "the intrinsic value of its parts, continued strong growth at Lexia, cost savings initiatives and its strong balance sheet."
F Ford
$11.20

0.14 (1.27%)

05/29/18
05/29/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ford (F) upgraded to Buy from Hold at Jefferies with analyst Philippe Houchois saying the company is getting no credit for its "ambitious but credible" cost targets and "strategic levers" to improve market and product exposure. 2. Roku (ROKU) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Benjamin Swinburne saying the shares are now down over 25% year-to-date while the company's "core fundamentals," such as ARPU and user growth, have been consistently coming in ahead of his prior expectations. 3. Phillips 66 (PSX) upgraded to Outperform from Market Perform at Wells Fargo with analyst Roger Read saying the IMO 2020 low sulfur marine fuel rule in his estimation will be a positive for the U.S. Independent Refiners. 4. Agnico Eagle (AEM) upgraded to Outperform from Market Perform at BMO Capital with analyst Andrew Kaip saying the company stands to benefit from "solid production growth" of 30% through 2020 following the addition of Meliadine assets into the pipeline and an improving free cash flow profile. 5. Occidental Petroleum (OXY) upgraded to Overweight from Equalweight at Capital One. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/29/18
JEFF
05/29/18
UPGRADE
Target $14
JEFF
Buy
Ford upgraded to Buy from Hold at Jefferies
Jefferies analyst Philippe Houchois upgraded Ford Motor to Buy and raised his price target for the shares to $14 from $13. The stock closed Friday down 11c to $11.51. The company is getting no credit for its "ambitious but credible" cost targets and "strategic levers" to improve market and product exposure, Houchois tells investors in a research note. The analyst thinks Ford is early among global carmakers in reevaluating how it allocates capital. Ford is his top pick among U.S. car manufacturers.
06/06/18
MSCO
06/06/18
NO CHANGE
MSCO
Morgan Stanley says Softbank stake in Cruise significant 'far beyond' just GM
Morgan Stanley analyst Adam Jonas said Softbank's (SFTBF) recently announced investment in GM Cruise "carries significance far beyond" General Motors (GM), arguing that the increasingly conspicuous involvement of "outside validators" such as large-cap tech firms and prominent investors can accelerate perception change in the capital markets about "Auto 2.0." He envisions the possible formation of two different companies currently held under one automaker's roof, which he dubs an Auto 2.0 "Yieldco" and an Auto 2.0 "Growthco." Converting car owners into monthly subscribers could open up significant revenue, profit, and value opportunities for traditional automakers, argues Jonas in a note to investors. Other automaking "OEMs" include Ford (F), Daimler (DDAIF), Toyota (TM), Honda (HMC), Fiat Chrysler (FCAU) and BMW Group (BAMXY).
06/06/18
MSCO
06/06/18
NO CHANGE
Target $16
MSCO
Overweight
Morgan Stanley questions if Ford has a 'business problem or a marketing problem'
Morgan Stanley analyst Adam Jonas estimate that Ford's F-Series pickup truck will produce $42B of revenues in 2018 and produce net income of approximately $6.5B. Excluding Ford Motor, he believes the F-Series franchise would rank #72 on the Fortune 500 list by revenues and that the F-Series ranks "well inside the top 50 companies" in the U.S. in terms of profitability. Given these estimates, Jonas wonders in his note to investors whether Ford has "a business problem or a marketing problem," questioning if the stock market just does "not appreciate the extremely large value of the F-Series business" or if it offsets this large value with "an implied large negative value" of over $10B for the rest of Ford's business. Jonas maintains an Overweight rating and $16 price target on Ford shares.
DPS Ticker changed to KDP
$0.00

(0.00%)

06/18/18
STFL
06/18/18
DOWNGRADE
STFL
Hold
Dr Pepper Snapple downgraded to Hold from Buy at Stifel
03/21/18
BMOC
03/21/18
NO CHANGE
Target $122
BMOC
Market Perform
Dr Pepper Snapple analyst day profiled rising coffee consumption, says BMO
BMO Capital analyst Amit Sharma keeps his Market Perform rating and $122 price target on Keurig Dr Pepper but notes that the company's analyst day has positioned it as an "attractive play" amid rising coffee consumption in multiple categories, formats, and channels. Sharma adds that despite his neutral stance on the stock, he is more positive about the company's ability to produce the $600M in cost synergies while also pointing to further margin expansion in the standalone Keurig Green Mountain business.
06/19/18
06/19/18
DOWNGRADE
Target $122

Hold
Dr Pepper downgraded to Hold on limited Keurig potential seen at Stifel
As previously reported, Stifel downgraded Dr Pepper Snapple to Hold from Buy, with analyst Mark Swartzberg telling investors that the more he learns about Keurig Green Mountain, the more he is convinced it has "limited capacity for operating income growth." The analyst, who recently reduced his Dr Pepper forecasts for higher packaging and logistics costs, has also lowered his KGM forecasts after reviewing a series of public filings. He keeps a price target of $122 on Dr Pepper shares to account for his 12-month stub target of $18.25 per share and the $103.75 special cash dividend that is scheduled to be paid.
06/19/18
06/19/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Mattel (MAT) downgraded to Neutral from Buy at UBS with analyst Arpine Kocharyan citing the stock's recent 35% appreciation with little change in fundamentals. 2. F5 Networks (FFIV) downgraded to Neutral from Buy at Citi with analyst Jim Suva saying with the stock up 38% year-to-date, the company's price-to-earnings valuation multiple has increased from 14.8 times at the start of the year to 17.8 times. 3. Dr Pepper Snapple (DPS) downgraded to Hold from Buy at Stifel with analyst Mark Swartzberg saying the more he learns about Keurig Green Mountain, the more he is convinced it has "limited capacity for operating income growth." 4. Red Hat (RHT) downgraded to Market Perform from Outperform at Raymond James with analyst Michael Turits saying shares are at peak valuation and the company is facing a difficult NTM growth outlook. 5. AT&T (T) downgraded to a Neutral after resuming coverage from Overweight at JPMorgan with analyst Philip Cusick saying he believes reversal of the Time Warner acquisition by the Department of Justice is "very unlikely" and would not be surprised to see AT&T shares "rebound fairly quickly after a period of deal-related flowback." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SIEGY Siemens
$0.00

(0.00%)

04/02/18
VERT
04/02/18
UPGRADE
VERT
Buy
Siemens upgraded to Buy from Hold at Vertical Research
12/11/17
MSCO
12/11/17
UPGRADE
MSCO
Overweight
Siemens upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Ben Uglow upgraded Siemens to Overweight with a price target of EUR 134.
12/05/17
LEHM
12/05/17
DOWNGRADE
LEHM
Underweight
Siemens downgraded to Underweight from Equal Weight at Barclays
Barclays analyst James Stettler downgraded Siemens to Underweight and lowered his price target for the shares to EUR 110 from EUR 125.
04/17/18
UBSW
04/17/18
NO CHANGE
UBSW
Buy
Siemens undervalued ahead of catalysts, says UBS
UBS analyst Markus Mittermaier believes Siemens shares have a price disconnect from the company's fundamentals. He noted there are issues weighing down the shares, such as India market issues and the gas turbine market forecast, but he believes these issues are understood. The analyst sees a number of catalysts ahead and believes investors should focus on the positive story. Mittermaier reiterated his Buy rating on Siemens shares.
GSK GlaxoSmithKline
$41.01

-0.01 (-0.02%)

06/13/18
MSCO
06/13/18
NO CHANGE
MSCO
HHS 'smoke signals' worth noting for drugmakers, says Morgan Stanley
After HHS Secretary Alex Azar spoke at a two-hour Senate hearing, Morgan Stanley analyst David Risinger noted that Azar suggested that U.S. drug pricing needs to move to a system without rebates and said payments from drugmakers to PBMs should be eliminated. In listing four HHS actions that could hurt manufacturers, Risinger pointed out that Azar said he is interested in removing 100% cap on Medicaid rebates; he would like to adjust the Part D protected drug classes so that plans can extract rebates from manufacturers; HHS wants to require manufacturers to disclose drug list prices in TV ads; and HHS is focused on transitioning Part B to lower-priced private sector management. In summary, the analyst said that for drugmakers there was "no fire, but smoke signals worth noting." Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
04/25/18
WELS
04/25/18
NO CHANGE
WELS
Market Perform
Glaxo comments on Advair have negative read through for Mylan, says Wells Fargo
Noting that GlaxoSmithKline (GSK) said it now expects branded Advair sales to decline 30% this year, even excluding the impact of a generic, Wells Fargo analyst David Maris said the news has a negative read through for Mylan (MYL) given that its generic Advair is one of the company's highest profile pipeline items. While Advair will be a good generic opportunity, it represents "a fraction of what some might have previously believed," said Maris, who has a Market Perform rating on Mylan shares.
05/16/18
SPHN
05/16/18
INITIATION
Target $16
SPHN
Overweight
Codexis initiated with an Overweight at Stephens
Stephens analyst Drew Jones started Codexis (CDXS) with an Overweight rating and $16 price target, stating that the company's CodeEvolver platform technology has been sought by pharma partners Merck (MRK), GlaxoSmithKline (GSK) and Nestle (NSRGY) and he expects continued deeper adoption from other major industry players.
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
ALL Allstate
$93.62

1.46 (1.58%)

05/18/18
SBSH
05/18/18
NO CHANGE
SBSH
Citi initiates pair trade of long Allstate, short Progressive
Citi analyst James Naklicki initiates a pair trade recommendation overweighting Allstate (ALL) and underweighting Progressive (PGR). The analyst, after reviewing the 2017 statutory results for the seven major lines of business within personal and commercial lines, found that in Personal Auto, the industry combined ratio improved by almost four points to 102.6%, far better than he was expecting. He thinks the industry is over-earning in workers comp.
06/06/18
BUCK
06/06/18
NO CHANGE
BUCK
Buckingham finds auto insurance placeholder on Amazon site
After an earlier article in "The Information" hinted that Amazon (AMZN) has contemplated offering home insurance in bundles with its smart devices, Buckingham analyst Amit Kumar said that when he went on Amazon's website, he found empty links/placeholders for "Financial Services" and "Auto Insurance," though he added he did not see a placeholder for "Homeowners." In terms of market share, Kumar said Allstate (ALL) is the most exposed to an Amazon entry to home, with 27% of its top line coming from Homeowners. In Personal Auto, Progressive (PGR) and Allstate are exposed with 82% and 68% of their premiums coming from auto insurance, the analyst stated. Other publicly traded companies in the insurance space include ACE Limited (ACE), AIG (AIG), Chubb (CB), Hartford Financial (HIG) and Travelers (TRV).
06/06/18
JPMS
06/06/18
NO CHANGE
JPMS
Amazon more likely to partner with home insurers, JPMorgan says
Insuring homes is a highly regulated business that requires major infrastructure to settle claims and the catastrophe exposure is significant, JPMorgan analyst Sarah DeWitt tells investors in a research note after The Information reported that Amazon.com (AMZN) is considering offering homeowner's Insurance. The analyst would be surprised if Amazon sought to fully manufacture homeowners' insurance and thinks a partnership with insurers would be more likely. Names in the property and casualty insurance space include Progressive (PGR), Allstate (ALL), Chubb (CB), Hartford Financial (HIG) and Travelers (TRV).
06/06/18
KBWI
06/06/18
NO CHANGE
KBWI
Amazon unlikely to overly disrupt insurance market, says Keefe Bruyette
Amazon.com's (AMZN) possible entry into homeowners insurance is unlikely to be "overly disruptive" to the industry, Keefe Bruyette analyst Meyer Shields told investors earlier in a research note. The analyst says that in the past, the U.S has been a relatively slow adopter of online insurance offerings. Names in the property and casualty insurance space include AIG (AIG), Allstate (ALL), Chubb (CB), Hartford Financial (HIG), Progressive (PGR) and Travelers (TRV).
VZ Verizon
$50.75

-0.13 (-0.26%)

06/21/18
GSCO
06/21/18
UPGRADE
GSCO
Buy
Goldman upgrades both Charter and Verizon to Buy from Neutral
Goldman Sachs analyst Brett Feldman upgraded both Charter Communications (CHTR) and Verizon Communications (VZ) to Buy from Neutral. The analyst raised his price target for Charter to $361 from $315 and for Verizon to $56 from $51. The year-to-date underperformance of the shares reflect concerns about fundamental headwinds, merger uncertainty and rising interest rates, Feldman tells investors in a research note partially titled "The pipes are not broken." The analyst, however, continues to believe both Charter and Verizon are positioned as long-term leaders in broadband and 5G. Both operators can drive attractive long-term shareholder returns by sustaining their core focus on connectivity, Feldman contends. He views the valuation of both companies as attractive at current share levels.
06/21/18
06/21/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. PayPal (PYPL) upgraded to Overweight from Neutral at Atlantic Equities with analyst Kunaal Malde saying he believes the company's differentiated checkout experience should enable the company to continue taking share. 2. Verizon (VZ) and Charter (CHTR) were upgraded to Buy from Neutral at Goldman Sachs. 3. Terex (TEX) upgraded to Buy from Hold at Jefferies with analyst Stephen Volkmann saying Terex has underperformed both the S&P 500 Index and machinery peers year-to-date despite improving backlog and visibility into 2019. 4. AMC Entertainment (AMC) upgraded to Buy from Hold at Benchmark with analyst Mike Hickey saying he believes the company's new movie subscription service will succeed in driving incremental attendance and EBITDA. 5. Becton Dickinson (BDX) upgraded to Overweight from Neutral at JPMorgan with analyst Robbie Marcus saying he sees a "clear path" for Becton to exceed expectations for the second half of 2018 and fiscal 2019 now that the Bard acquisition is two quarters in. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/21/18
RHCO
06/21/18
NO CHANGE
Target $58
RHCO
Buy
Verizon fundamentals have stabilized, says SunTrust
SunTrust analyst Greg Miller kept his Buy rating and $58 price target on Verizon after his meetings with its management, saying he is increasingly confident that there won't be another large-scale M&A event as has been the case with its many peers and that its fundamentals have also stabilized. Miller also maintains his view that the stock valuation offers downside protection while the benefits of U.S. tax reform remain "largely underappreciated".
06/21/18
GSCO
06/21/18
UPGRADE
Target $56
GSCO
Buy
Verizon upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Brett Feldman upgraded Verizon Communications to Buy and raised his price target for the shares to $56 from $51.
SAP SAP
$119.25

2.26 (1.93%)

04/24/18
DBAB
04/24/18
NO CHANGE
DBAB
SAP removed from the short-term buy list at Deutsche Bank
05/18/18
DADA
05/18/18
NO CHANGE
Target $31
DADA
Neutral
ProsHoldings price target raised to $31 from $28 at DA Davidson
DA Davidson analyst Rishi Jaluria raised his price target on ProsHoldings (PRO) to $31 following its user conference and investor session. The analyst cites the company's disclosed partnership with SAP Hybris (SAP) on joint projects in airline solutions and its "solid" expansion outside of travel. While Jaluria anticipates incremental benefits from the partnership, he keeps his Neutral rating due to valuation and worries about ProsHoldings' cash burn.
06/01/18
JEFF
06/01/18
INITIATION
Target $140
JEFF
Buy
SAP initiated with a Buy at Jefferies
Jefferies analyst Vijay Anand started SAP with a Buy rating and $140 price target. The analyst views the slower than expected progress in SAP's cloud gross margin improvement as "largely a timing issue." With the investment phase mostly over, the analyst expects SAP's free cash flow growth to accelerate and shares to re-rate as investors "fully appreciate the quality" of its cloud assets.
03/12/18
03/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Time Warner (TWX) upgraded to Buy from Neutral at UBS with analyst John Hodulik saying while he expects the takeover by AT&T (T) to receive regulatory approval, he believes the current environment would make Time Warner's assets "highly attractive" to other media companies and Internet-based competitors were the deal to be blocked. 2. Carlyle Group (CG) and Apollo Global (APO) were upgraded to Buy from Neutral at Citi. 3. Merck (MRK) upgraded to Outperform from Market Perform at Leerink with analyst Seamus Fernandez saying Keytruda will continue to dominate the first-line non-small cell lung cancer market. 4. SAP (SAP) upgraded to Outperform from In Line at Evercore ISI with analyst Stewart Materne III saying that he believes the risk/reward is more attractive at current levels following the stock's 6% pullback. 5. Aratana Therapeutics (PETX) upgraded to Buy on valuation at CL King with the firm citing favorable risk/reward. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
OTEX OpenText
$36.94

0.51 (1.40%)

05/09/18
MUFG
05/09/18
NO CHANGE
Target $47
MUFG
Overweight
OpenText price target lowered to $47 from $50 at MUFG
MUFG analyst Stephen Bersey lowered his price target on OpenText to $47 after its Q3 results, saying the earnings miss was likely driven by the push forward of certain license deals into Q2 given that license revenue undershot estimates by about $30M. Despite the miss, Bersey recommends the stock over the longer term and keeps his Overweight rating, noting that the company has "aligned itself with high growth markets", and its FY21 targets underscore its "confidence in operations". In afterhours trading, OpenText shares were down 9.8% at $33 per share.
02/01/18
MUFG
02/01/18
NO CHANGE
Target $50
MUFG
Overweight
OpenText price target raised to $50 from $40 at MUFG
MUFG analyst Stephen Bersey raised his price target for OpenText to $50 after the company "handily beat" his estimates for Q2. OpenText "had a great quarter," Bersey tells investors in a post-earnings research note. The analyst keeps an Overweight rating on the shares.
11/22/17
RAJA
11/22/17
NO CHANGE
Target $40
RAJA
Outperform
Raymond James remains bullish on OpenText despite competitor downgrade
Raymond James analyst Steven Li notes that a competitor downgraded OpenText this morning to an Underperform rating, saying Constellation Software has a much stronger balance sheet. The analyst argues that it is "stating the obvious," given that OpenText just made the largest acquisition in its history. This logic does not hold historically, he notes. While Li acknowledges that Constellation Software has much higher return on capital, and may have better growth and cash return prospects, he points out that its competitor report does not highlight the recent turn in organic growth. The analyst reiterates an Outperform rating and $40 price target on OpenText's shares.
11/22/17
MACQ
11/22/17
DOWNGRADE
Target $31.5
MACQ
Underperform
OpenText downgraded to Underperform from Neutral at Macquarie
Macquarie analyst Gus Papageorgiou downgraded OpenText to Underperform and lowered its price target to $31.50 from 34.50. The analyst said OpenText has highly recurring and profitable operations but poor returns on capital and limited growth due to a leveraged balance sheet.

TODAY'S FREE FLY STORIES

TRCH

Torchlight Energy Resources

$0.91

-0.0184 (-1.98%)

06:07
10/17/18
10/17
06:07
10/17/18
06:07
Conference/Events
Torchlight Energy Resources management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

RYTM

Rhythm Pharmaceuticals

$28.09

1.56 (5.88%)

06:06
10/17/18
10/17
06:06
10/17/18
06:06
Conference/Events
Rhythm Pharmaceuticals management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

TSLA

Tesla

$276.46

16.88 (6.50%)

06:06
10/17/18
10/17
06:06
10/17/18
06:06
Periodicals
Tesla secures site in Shanghai for new Gigafactory, Reuters reports »

Tesla has signed an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 13

    Nov

  • 13

    Dec

AKRX

Akorn

$6.71

0.445 (7.11%)

06:06
10/17/18
10/17
06:06
10/17/18
06:06
Upgrade
Akorn rating change  »

Akorn upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAXR

Maxar Technologies

$30.39

0.98 (3.33%)

06:06
10/17/18
10/17
06:06
10/17/18
06:06
Hot Stocks
Maxar Technologies subsidiary awarded up to $7M NASA contract »

DigitalGlobe, a Maxar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMUC

ImmunoCellular

$0.05

-0.173 (-76.55%)

06:03
10/17/18
10/17
06:03
10/17/18
06:03
Hot Stocks
ImmunoCellular receives notice of noncompliance from NYSE, stock to be delisted »

ImmunoCellular announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RSNAY

RSA Insurance

$0.00

(0.00%)

06:03
10/17/18
10/17
06:03
10/17/18
06:03
Conference/Events
RSA Insurance management to meet with RBC Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

MEI

Methode Electronics

$30.08

0.73 (2.49%)

06:03
10/17/18
10/17
06:03
10/17/18
06:03
Conference/Events
Methode Electronics management to meet with B. Riley FBR »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CNCE

Concert Pharmaceuticals

$15.59

0.64 (4.28%)

06:01
10/17/18
10/17
06:01
10/17/18
06:01
Conference/Events
Concert Pharmaceuticals management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

LYFT

Lyft

$0.00

(0.00%)

, JPM

JPMorgan

$108.65

2.31 (2.17%)

06:00
10/17/18
10/17
06:00
10/17/18
06:00
Periodicals
Lyft picks JPMorgan to lead IPO, which could be valued at over $15B, CNBC says »

Lyft (LYFT) has hired…

LYFT

Lyft

$0.00

(0.00%)

JPM

JPMorgan

$108.65

2.31 (2.17%)

UBER

Uber

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 21

    Oct

  • 24

    Oct

  • 26

    Feb

ALB

Albemarle

$97.15

1.02 (1.06%)

06:00
10/17/18
10/17
06:00
10/17/18
06:00
Conference/Events
Albemarle management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 08

    Nov

BMO

Bank of Montreal

$80.19

0.93 (1.17%)

05:59
10/17/18
10/17
05:59
10/17/18
05:59
Conference/Events
Bank of Montreal to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 24

    Oct

TWTR

Twitter

$29.86

1.25 (4.37%)

05:57
10/17/18
10/17
05:57
10/17/18
05:57
Periodicals
Twitter banned 1,500 accounts for misleading election-related content, NYT says »

Over the weekend, Twitter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

TSLA

Tesla

$276.46

16.88 (6.50%)

05:57
10/17/18
10/17
05:57
10/17/18
05:57
Hot Stocks
Tesla's Musk vows to fix 'foolish oversight' in service locations »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 13

    Nov

  • 13

    Dec

GOOG

Alphabet

$1,120.11

28.11 (2.57%)

, GOOGL

Alphabet Class A

$1,133.71

32.13 (2.92%)

05:52
10/17/18
10/17
05:52
10/17/18
05:52
Hot Stocks
YouTube resolves widespread access issues also impacgint YouTube TV, Music »

YouTube says it has…

GOOG

Alphabet

$1,120.11

28.11 (2.57%)

GOOGL

Alphabet Class A

$1,133.71

32.13 (2.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 03

    Mar

SSNLF

Samsung

$0.00

(0.00%)

05:50
10/17/18
10/17
05:50
10/17/18
05:50
Hot Stocks
Samsung to acquire Zhilabs to expand AI-based automation portfolio »

Samsung Electronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,818.00

57.01 (3.24%)

05:47
10/17/18
10/17
05:47
10/17/18
05:47
Periodicals
Amazon employee on Medium: Employees asked Bezos to kick Palantir off AWS »

An anonymous Amazon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 25

    Oct

LOW

Lowe's

$105.97

1.31 (1.25%)

05:41
10/17/18
10/17
05:41
10/17/18
05:41
Downgrade
Lowe's rating change  »

Lowe's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

HD

Home Depot

$193.61

2.51 (1.31%)

05:40
10/17/18
10/17
05:40
10/17/18
05:40
Downgrade
Home Depot rating change  »

Home Depot downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLCA

U.S. Silica

$18.72

0.38 (2.07%)

05:40
10/17/18
10/17
05:40
10/17/18
05:40
Downgrade
U.S. Silica rating change  »

U.S. Silica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

CVIA

Covia

$7.58

0.18 (2.43%)

05:39
10/17/18
10/17
05:39
10/17/18
05:39
Downgrade
Covia rating change  »

Covia downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SND

Smart Sand

$3.81

-0.07 (-1.80%)

05:39
10/17/18
10/17
05:39
10/17/18
05:39
Downgrade
Smart Sand rating change  »

Smart Sand downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCLP

Hi-Crush Partners

$9.49

-0.16 (-1.66%)

05:38
10/17/18
10/17
05:38
10/17/18
05:38
Downgrade
Hi-Crush Partners rating change  »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

SCGLY

Societe Generale

$0.00

(0.00%)

, BNPQY

BNP Paribas

$0.00

(0.00%)

05:38
10/17/18
10/17
05:38
10/17/18
05:38
Periodicals
Societe Generale CEO pulls out of Saudi Arabia summit, Reuters reports »

Societe Generale (SCGLY)…

SCGLY

Societe Generale

$0.00

(0.00%)

BNPQY

BNP Paribas

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAFRY

Safran

$0.00

(0.00%)

05:37
10/17/18
10/17
05:37
10/17/18
05:37
Downgrade
Safran rating change  »

Safran downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.